• Explore /
  • Poster
  • / Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial.

Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial.

Abstract Poster

Authors

Ryan Cassaday

Ryan Daniel Cassaday

University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA

Ryan Daniel Cassaday , Daniel J. DeAngelo , Giovanni Martinelli , Wendy Stock , Matthias Stelljes , Nicola Gökbuget , Anjali S. Advani , Susan Mary O'Brien , Michaela Liedtke , Akil Abid Merchant , Tao Wang , Erik Vandendries , David I. Marks , Elias Jabbour , Hagop M. Kantarjian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01564784

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7029)

DOI

10.1200/JCO.2018.36.15_suppl.7029

Abstract #

7029

Poster Bd #

89

Abstract Disclosures

Similar Posters

First Author: Marcos J.G. De Lima

First Author: Elias Jabbour

First Author: Elias Jabbour

Poster

2023 ASCO Annual Meeting

Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.

Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.

First Author: Sophie Cousin